309.6K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Terry C. Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.69 per share. | 12 Feb 2025 | 45,000 | 846,638 (4%) | 0% | 5.7 | 256,050 | Common Stock |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 7,484 | 864,654 (4%) | 0% | 5.6 | 41,836 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 25,500 | 872,138 (4%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 4,324 | 374,535 (1%) | 0% | 5.6 | 24,171 | Common Stock |
| Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 9,750 | 378,859 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 95,884 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Paul J. Mellett | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 99,210 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 36,805 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 33,479 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Brendan Luu | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 40,221 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Brendan Luu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 43,547 (0%) | 0% | 0 | Common Stock | |
| Scott T. Rottinghaus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 9,750 | 27,668 (0%) | 0% | 0 | Common Stock | |
| Scott T. Rottinghaus | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 2,861 | 24,807 (0%) | 0% | 5.6 | 15,993 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 5,142 | 801,638 (4%) | 0% | 8.1 | 41,445 | Common Stock |
| Yat Sun Or | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,591 | 369,109 (1%) | 0% | 8.1 | 20,883 | Common Stock |
| Paul J. Mellett | Chief Fin. & Admin Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,591 | 91,710 (0%) | 0% | 8.1 | 20,883 | Common Stock |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,283 | 29,305 (0%) | 0% | 8.1 | 18,401 | Common Stock |
| Brendan Luu | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,283 | 36,047 (0%) | 0% | 8.1 | 18,401 | Common Stock |
| Scott T. Rottinghaus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 866 | 17,918 (0%) | 0% | 8.1 | 6,980 | Common Stock |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 3,829 | 806,780 (4%) | 0% | 8.6 | 32,929 | Common Stock |
| Yat Sun Or | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 1,595 | 371,700 (1%) | 0% | 8.6 | 13,717 | Common Stock |
| Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 1,595 | 94,301 (0%) | 0% | 8.6 | 13,717 | Common Stock |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 753 | 31,588 (0%) | 0% | 8.6 | 6,476 | Common Stock |
| Brendan Luu | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 753 | 38,330 (0%) | 0% | 8.6 | 6,476 | Common Stock |
| Luly Jay R. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Luu Brendan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Rottinghaus T. Scott | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Mellett J. Paul | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 81,000 | 81,000 | - | - | Stock Option (right to buy) | |
| Or Yat Sun | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Lynn Tara Kieffer | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 81,000 | 81,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 5,375 | 80,625 | - | - | Stock Option (Right to Buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.08 per share. | 11 Jul 2024 | 5,375 | 21,717 (0%) | 0% | 17.1 | 91,805 | Common Stock |
| Scott T. Rottinghaus | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.99 per share. | 11 Jul 2024 | 5,375 | 27,092 (0%) | 0% | 9.0 | 48,321 | Common Stock |
| Scott T. Rottinghaus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 11 Jul 2024 | 2,271 | 21,717 (0%) | 0% | 15.0 | 34,156 | Common Stock |
| Scott T. Rottinghaus | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 11 Jul 2024 | 4,299 | 23,988 (0%) | 0% | 15.1 | 64,786 | Common Stock |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Sale of securities on an exchange or to another person at price $ 12.33 per share. | 17 Jun 2024 | 7,266 | 32,341 (0%) | 0% | 12.3 | 89,590 | Common Stock |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Terry C. Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| S. Nathaniel Gardiner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.99 per share. | 26 Feb 2024 | 5,187 | 75,688 (0%) | 0% | 9.0 | 46,631 | Common Stock |
| S. Gardiner Nathaniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,187 | 77,813 | - | - | Stock Option (Right to Buy) | |
| Luu Brendan | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 39,083 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| T. Rottinghaus Scott | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 2,576 | 29,042 (0%) | 0% | 0 | Common Stock | |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 39,607 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,680 | 374,375 (1%) | 0% | 0 | Common Stock | |
| T. Scott Rottinghaus | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 755 | 28,287 (0%) | 0% | 12.4 | 9,370 | Common Stock |
| R. Jay Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 5,400 | 812,193 (4%) | 0% | 0 | Common Stock | |
| Brendan Luu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 40,056 (0%) | 0% | 0 | Common Stock | |
| S. Gardiner Nathaniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 70,501 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| R. Luly Jay | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 1,584 | 810,609 (4%) | 0% | 12.4 | 19,657 | Common Stock |
| Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 95,896 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Yat Sun Or | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 1,080 | 373,295 (1%) | 0% | 12.4 | 13,403 | Common Stock |
| J. Mellett Paul | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 96,869 (0%) | 0% | 0 | Common Stock | |
| Nathaniel Gardiner S. | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 71,474 (0%) | 0% | 0 | Common Stock | |
| Kieffer Lynn Tara | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 40,580 (0%) | 0% | 0 | Common Stock | |
| C Terry Vance | Director | Sale of securities on an exchange or to another person at price $ 9.12 per share. | 13 Dec 2023 | 15,295 | 5,800 (0%) | 0% | 9.1 | 139,490 | Common Stock |
| T. Scott Rottinghaus | Sr. VP & CMO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 534 | 26,466 (0%) | 0% | 9.6 | 5,142 | Common Stock |
| Lynn Tara Kieffer | Sr. VP, New Prod. Strat. & Dev | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,125 | 37,260 (0%) | 0% | 9.6 | 20,464 | Common Stock |
| R. Jay Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 7,230 | 806,793 (4%) | 0% | 9.6 | 69,625 | Common Stock |
| J. Paul Mellett | Sr. VP, Finance & Admin. & CFO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 93,549 (0%) | 0% | 9.6 | 23,228 | Common Stock |
| Brendan Luu | Sr. VP, Business Dev. | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,125 | 36,736 (0%) | 0% | 9.6 | 20,464 | Common Stock |
| S. Nathaniel Gardiner | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 68,154 (0%) | 0% | 9.6 | 23,228 | Common Stock |
| Sun Or Yat | Sr. VP, R&D & CSO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 370,695 (1%) | 0% | 9.6 | 23,228 | Common Stock |
| Yat Sun Or | Sr. VP, R&D & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 373,107 (1%) | 0% | 9.5 | 15,137 | Common Stock |
| Tara Lynn Kieffer | Sr. VP, New Prod. Strat. & Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 753 | 39,385 (0%) | 0% | 9.5 | 7,146 | Common Stock |
| Luu Brendan | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 753 | 38,861 (0%) | 0% | 9.5 | 7,146 | Common Stock |
| R. Luly Jay | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 5,787 | 814,023 (4%) | 0% | 9.5 | 54,919 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 70,566 (0%) | 0% | 9.5 | 15,137 | Common Stock |
| Paul J. Mellett | Sr. VP, Finance & Admin. & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 95,961 (0%) | 0% | 9.5 | 15,137 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 264,000 | 264,000 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP, R&D & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 86,000 | 86,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Sr. VP, Finance & Admin. & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Tara Lynn Kieffer | Sr. VP, New Prod. Strat. & Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Sr. VP & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 86,000 | 86,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.23 per share. | 08 Aug 2023 | 1,467 | 25,533 (0%) | 0% | 17.2 | 25,276 | Common Stock |
| Scott T. Rottinghaus | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.73 per share. | 08 Aug 2023 | 1,466 | 18,784 (0%) | 0% | 12.7 | 18,662 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2023 | 6,667 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 18 Apr 2023 | 6,667 | 79,980 (0%) | 0% | 30 | 200,010 | Common Stock |
| Terry C Vance | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 16 Mar 2023 | 5,800 | 21,095 (0%) | 0% | 14 | 81,200 | Common Stock |
| Terry C Vance | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 5,800 | 0 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 15 Mar 2023 | 13,925 | 388,627 (1%) | 0% | 14 | 194,950 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 13,925 | 0 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 44.46 per share. | 15 Mar 2023 | 13,656 | 374,702 (1%) | 0% | 44.5 | 607,146 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 43.92 per share. | 15 Mar 2023 | 269 | 388,358 (1%) | 0% | 43.9 | 11,814 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 15 Mar 2023 | 10,440 | 107,996 (0%) | 0% | 14 | 146,160 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 10,440 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 44.43 per share. | 15 Mar 2023 | 10,340 | 97,556 (0%) | 0% | 44.4 | 459,406 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 43.96 per share. | 15 Mar 2023 | 100 | 107,896 (0%) | 0% | 44.0 | 4,396 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 13 Mar 2023 | 27,912 | 847,722 (4%) | 0% | 14 | 390,768 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2023 | 27,912 | 0 | - | - | Stock Option (Right to Buy) | |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.13 per share. | 13 Mar 2023 | 1,566 | 819,810 (4%) | 0% | 46.1 | 72,240 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.31 per share. | 13 Mar 2023 | 15,649 | 821,376 (4%) | 0% | 45.3 | 709,056 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.81 per share. | 13 Mar 2023 | 10,697 | 837,025 (4%) | 0% | 44.8 | 479,333 | Common Stock |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Terry C Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 22,950 | 811,255 (4%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 29,146 | 840,401 (4%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 20,591 | 819,810 (4%) | 0% | 52.8 | 1,086,587 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 7,752 | 374,702 (1%) | 0% | 52.8 | 409,073 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,250 | 369,437 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 13,017 | 382,454 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 104,460 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,904 | 97,556 (0%) | 0% | 52.8 | 364,324 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 92,713 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,735 | 73,313 (0%) | 0% | 52.8 | 355,406 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 68,301 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 80,048 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 35,116 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,725 | 40,138 (0%) | 0% | 52.8 | 354,878 | Common Stock |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 46,863 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 8,945 | 34,670 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,360 | 46,030 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,416 | 39,614 (0%) | 0% | 52.8 | 338,572 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 09 Feb 2023 | 800 | 83,463 (0%) | 0% | 54.4 | 43,528 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 53.64 per share. | 09 Feb 2023 | 4,200 | 84,263 (0%) | 0% | 53.6 | 225,288 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 2,812 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 09 Jan 2023 | 2,812 | 88,463 (0%) | 0% | 14.2 | 39,874 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 14,500 | 55,500 | - | - | Stock Option (Right to Buy) | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.58 per share. | 19 Dec 2022 | 14,500 | 788,305 (3%) | 0% | 27.6 | 399,910 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 4,148 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 19 Dec 2022 | 4,148 | 85,651 (0%) | 0% | 14.2 | 58,819 | Common Stock |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 5,659 | 773,805 (3%) | 0% | 44.3 | 250,863 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 359,187 (1%) | 0% | 44.3 | 46,768 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 81,503 (0%) | 0% | 44.3 | 46,768 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 59,051 (0%) | 0% | 44.3 | 46,768 | Common Stock |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 498 | 25,866 (0%) | 0% | 44.3 | 22,076 | Common Stock |
| Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 498 | 25,725 (0%) | 0% | 44.3 | 22,076 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 63,000 | 779,464 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 134,000 | 134,000 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 360,242 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 82,558 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 60,106 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 18,500 | 26,364 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 18,500 | 26,223 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 7,000 | 27,000 (0%) | 0% | 0 | Common Stock | |
| Scott T. Rottinghaus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Scott T. Rottinghaus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 3,480 | 0 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 17 Jun 2022 | 3,480 | 61,558 (0%) | 0% | 11.8 | 40,960 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 16,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.42 per share. | 01 Apr 2022 | 16,000 | 50,982 (0%) | 0% | 31.4 | 502,720 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 01 Apr 2022 | 31,664 | 82,646 (0%) | 0% | 30 | 949,920 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Apr 2022 | 2,895 | 85,541 (0%) | 0% | 48.5 | 140,465 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.75 per share. | 01 Apr 2022 | 8,299 | 77,242 (0%) | 0% | 70.7 | 587,154 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.32 per share. | 01 Apr 2022 | 42,260 | 34,982 (0%) | 0% | 71.3 | 3,013,983 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Apr 2022 | 6,285 | 41,267 (0%) | 0% | 48.5 | 304,948 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.57 per share. | 01 Apr 2022 | 9,625 | 50,892 (0%) | 0% | 43.6 | 419,361 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.35 per share. | 01 Apr 2022 | 16,875 | 67,767 (0%) | 0% | 63.3 | 1,069,031 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.56 per share. | 01 Apr 2022 | 2,500 | 65,267 (0%) | 0% | 70.6 | 176,400 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.71 per share. | 01 Apr 2022 | 18,076 | 47,191 (0%) | 0% | 71.7 | 1,296,230 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 01 Apr 2022 | 3,200 | 43,991 (0%) | 0% | 72.7 | 232,480 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 73.42 per share. | 01 Apr 2022 | 9,009 | 34,982 (0%) | 0% | 73.4 | 661,441 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 31,664 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 2,895 | 6,285 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 6,285 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 9,625 | 21,175 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 16,875 | 13,125 | - | - | Stock Option (Right to Buy) | |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 69.52 per share. | 21 Mar 2022 | 807 | 0 (0%) | 0% | 69.5 | 56,103 | Common Stock |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 68.66 per share. | 21 Mar 2022 | 2,210 | 807 (0%) | 0% | 68.7 | 151,739 | Common Stock |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 67.23 per share. | 21 Mar 2022 | 307 | 3,017 (0%) | 0% | 67.2 | 20,640 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.58 per share. | 21 Mar 2022 | 6,000 | 6,000 (0%) | 0% | 25.6 | 153,480 | Common Stock |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 66.70 per share. | 21 Mar 2022 | 2,676 | 3,324 (0%) | 0% | 66.7 | 178,489 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Terry C Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.06 per share. | 01 Mar 2022 | 100 | 34,982 (0%) | 0% | 71.1 | 7,106 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.07 per share. | 01 Mar 2022 | 12,481 | 34,982 (0%) | 0% | 70.1 | 874,544 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 24,339 | 12,481 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.26 per share. | 01 Mar 2022 | 24,239 | 35,082 (0%) | 0% | 70.3 | 1,703,032 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 01 Mar 2022 | 24,339 | 59,321 (0%) | 0% | 43.5 | 1,057,773 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 12,481 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 01 Mar 2022 | 12,481 | 47,463 (0%) | 0% | 43.5 | 542,424 | Common Stock |
| Jay R. Luly | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 6,401 | 718,819 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,627 | 712,418 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 2,355 | 716,464 (3%) | 0% | 62.5 | 147,164 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 340,195 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 953 | 339,242 (1%) | 0% | 62.5 | 59,553 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 337,776 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 958 | 58,078 (0%) | 0% | 62.5 | 59,865 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 56,617 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 59,036 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 47,196 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 957 | 46,239 (0%) | 0% | 62.5 | 59,803 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 44,777 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 954 | 34,982 (0%) | 0% | 62.5 | 59,615 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 33,517 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 35,936 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 327 | 7,127 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,289 | 8,416 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 552 | 7,864 (0%) | 0% | 62.5 | 34,494 | Common Stock |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 286 | 7,086 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,126 | 8,212 (0%) | 0% | 0 | Common Stock | |
| Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 489 | 7,723 (0%) | 0% | 62.5 | 30,558 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2022 | 10,063 | 0 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 15 Jan 2022 | 10,063 | 710,791 (3%) | 0% | 11.8 | 118,442 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 9,200 | 36,820 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 3,336 | 31,664 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 11 Jan 2022 | 3,336 | 45,438 (0%) | 0% | 30 | 100,080 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 11 Jan 2022 | 9,200 | 42,102 (0%) | 0% | 43.5 | 399,832 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.13 per share. | 11 Jan 2022 | 12,536 | 32,902 (0%) | 0% | 70.1 | 879,150 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 25,700 | 702,672 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 107,800 | 107,800 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 337,718 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 56,559 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 59,783 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 33,744 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 6,800 (0%) | 0% | 0 | Common Stock | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 6,800 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.02 per share. | 01 Nov 2021 | 7,495 | 27,044 (0%) | 0% | 85.0 | 637,225 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 9,547 | 13,953 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.31 per share. | 01 Nov 2021 | 1,952 | 34,539 (0%) | 0% | 84.3 | 164,573 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Nov 2021 | 9,547 | 36,491 (0%) | 0% | 48.5 | 463,220 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 86.21 per share. | 01 Nov 2021 | 100 | 26,944 (0%) | 0% | 86.2 | 8,621 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 4,047 | 54,770 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 08 Oct 2021 | 13,453 | 40,397 (0%) | 0% | 43.5 | 584,667 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.09 per share. | 08 Oct 2021 | 13,453 | 26,944 (0%) | 0% | 70.1 | 942,934 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 08 Oct 2021 | 4,047 | 30,991 (0%) | 0% | 43.5 | 175,883 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.34 per share. | 08 Oct 2021 | 4,047 | 26,944 (0%) | 0% | 70.3 | 284,685 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 13,453 | 58,817 | - | - | Stock Option (Right to Buy) | |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.06 per share. | 15 Sep 2021 | 4,516 | 676,972 (3%) | 0% | 59.1 | 266,698 | Common Stock |
| Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2021 | 13,144 | 13,144 | - | - | Stock Option (right to buy) | |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Terry C Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 26 Jan 2021 | 3,672 | 326,046 (1%) | 0% | 11.8 | 43,219 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 4,872 | 0 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 3,672 | 0 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 5,149 | 0 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 26 Jan 2021 | 4,872 | 330,918 (1%) | 0% | 11.8 | 57,343 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 26 Jan 2021 | 5,149 | 322,374 (1%) | 0% | 14.2 | 73,013 | Common Stock |
| Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 45.58 per share. | 08 Jan 2021 | 6,000 | 61,759 (0%) | 0% | 45.6 | 273,463 | Common Stock |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 2,201 | 681,488 (3%) | 0% | 42.5 | 93,587 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 7,500 | 683,689 (3%) | 0% | - | Common Stock | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 7,500 | 0 | - | - | Restricted Stock Units | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 1,540 | 317,225 (1%) | 0% | 42.5 | 65,481 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 318,765 (1%) | 0% | - | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 0 | - | - | Restricted Stock Units | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,625 | 56,529 (0%) | 0% | - | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,625 | 0 | - | - | Restricted Stock Units | |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 770 | 55,759 (0%) | 0% | 42.5 | 32,740 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 0 | - | - | Restricted Stock Units | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 1,540 | 42,248 (0%) | 0% | 42.5 | 65,481 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 43,788 (0%) | 0% | - | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 1,540 | 26,944 (0%) | 0% | 42.5 | 65,481 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 28,484 (0%) | 0% | - | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 0 | - | - | Restricted Stock Units | |
| Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2020 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 03 Dec 2020 | 1,667 | 38,538 (0%) | 0% | 30 | 50,010 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2020 | 1,667 | 13,667 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 107,800 | 107,800 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 26,500 | 676,189 (3%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 313,515 (1%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 53,904 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 36,871 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 23,234 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 3,480 | 0 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.54 per share. | 11 Nov 2020 | 3,480 | 46,304 (0%) | 0% | 2.5 | 8,849 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2020 | 1,666 | 15,334 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 05 Aug 2020 | 1,666 | 29,271 (0%) | 0% | 30 | 49,980 | Common Stock |
| Mark G. Foletta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2020 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.21 per share. | 05 May 2020 | 1,740 | 42,824 (0%) | 0% | 1.2 | 2,100 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 1,740 | 0 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2020 | 3,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 12 Mar 2020 | 3,000 | 27,605 (0%) | 0% | 30 | 90,000 | Common Stock |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Terry C Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| George Golumbeski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 8,910 | 652,811 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.76 per share. | 12 Feb 2020 | 3,122 | 649,689 (3%) | 0% | 52.8 | 164,717 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 1,485 | 643,901 (3%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 2,925 | 307,004 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 487 | 304,079 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.76 per share. | 12 Feb 2020 | 1,089 | 305,915 (1%) | 0% | 52.8 | 57,456 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 1,350 | 41,629 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.76 per share. | 12 Feb 2020 | 545 | 41,084 (0%) | 0% | 52.8 | 28,754 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 225 | 40,279 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.76 per share. | 12 Feb 2020 | 940 | 24,605 (0%) | 0% | 52.8 | 49,594 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 412 | 23,070 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 2,475 | 25,545 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 2,925 | 16,725 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.76 per share. | 12 Feb 2020 | 1,091 | 15,634 (0%) | 0% | 52.8 | 57,561 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 487 | 13,800 (0%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 7,500 | 645,746 (3%) | 0% | - | Common Stock | |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.88 per share. | 16 Dec 2019 | 3,330 | 642,416 (3%) | 0% | 63.9 | 212,720 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 305,923 (1%) | 0% | - | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 5,250 | - | - | Restricted Stock Units | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.88 per share. | 16 Dec 2019 | 2,331 | 303,592 (1%) | 0% | 63.9 | 148,904 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.88 per share. | 16 Dec 2019 | 1,165 | 50,054 (0%) | 0% | 63.9 | 74,420 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 2,625 | 51,219 (0%) | 0% | - | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 2,625 | 2,625 | - | - | Restricted Stock Units | |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 61.66 per share. | 16 Dec 2019 | 721 | 40,054 (0%) | 0% | 61.7 | 44,458 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 60.82 per share. | 16 Dec 2019 | 9,279 | 40,775 (0%) | 0% | 60.8 | 564,341 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 24,989 (0%) | 0% | - | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.88 per share. | 16 Dec 2019 | 2,331 | 22,658 (0%) | 0% | 63.9 | 148,904 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 5,250 | - | - | Restricted Stock Units | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 5,250 | - | - | Restricted Stock Units | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,250 | 15,644 (0%) | 0% | - | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.88 per share. | 16 Dec 2019 | 2,331 | 13,313 (0%) | 0% | 63.9 | 148,904 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.42 per share. | 22 Nov 2019 | 1,592 | 19,739 (0%) | 0% | 31.4 | 50,021 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2019 | 1,592 | 19,818 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2019 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2019 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2019 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2019 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2019 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2019 | 7,052 | 16,149 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 08 Oct 2019 | 7,052 | 638,246 (3%) | 0% | 14.2 | 99,997 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 27 Sep 2019 | 5,000 | 19,871 (0%) | 0% | 30 | 150,000 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2019 | 5,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.42 per share. | 26 Jun 2019 | 3,295 | 13,147 (0%) | 0% | 31.4 | 103,529 | Common Stock |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 99.16 per share. | 11 Mar 2019 | 1,546 | 0 (0%) | 0% | 99.2 | 153,301 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2019 | 1,546 | 0 | - | - | Stock Option (Right to Buy) | |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.40 per share. | 11 Mar 2019 | 1,546 | 1,546 (0%) | 0% | 23.4 | 36,176 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.42 per share. | 06 Mar 2019 | 795 | 26,497 (0%) | 0% | 31.4 | 24,979 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2019 | 795 | 24,705 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2019 | 1,724 | 70,976 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.70 per share. | 06 Mar 2019 | 1,724 | 25,702 (0%) | 0% | 34.7 | 59,823 | Common Stock |
| George Golumbeski | Director | Sale of securities on an exchange or to another person at price $ 103.65 per share. | 04 Mar 2019 | 9,280 | 0 (0%) | 0% | 103.7 | 961,897 | Common Stock |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2019 | 9,280 | 0 | - | - | Stock Option (Right to Buy) | |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.61 per share. | 04 Mar 2019 | 9,280 | 9,280 (0%) | 0% | 36.6 | 339,741 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 103.32 per share. | 01 Mar 2019 | 5,910 | 304,763 (1%) | 0% | 103.3 | 610,628 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 103.84 per share. | 01 Mar 2019 | 4,090 | 300,673 (1%) | 0% | 103.8 | 424,693 | Common Stock |
| Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Lesley Russell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Stephen Buckley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Terry C Vance | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| George Golumbeski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.51 per share. | 13 Feb 2019 | 6,960 | 97,188 (0%) | 0% | 1.5 | 10,499 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2019 | 6,960 | 0 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 12 Feb 2019 | 20,730 | 631,194 (3%) | 0% | 88.9 | 1,842,482 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 14,400 | 615,924 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 36,000 | 651,924 (3%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 10,500 | 95,118 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 4,200 | 84,618 (0%) | 0% | 0 | Common Stock | |
| Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 12 Feb 2019 | 4,890 | 90,228 (0%) | 0% | 88.9 | 434,623 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 4,000 | 12,127 (0%) | 0% | 0 | Common Stock | |
| Timothy D. Ocain | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 10,000 | 22,127 (0%) | 0% | 0 | Common Stock | |
| Timothy D. Ocain | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 12 Feb 2019 | 4,580 | 17,547 (0%) | 0% | 88.9 | 407,070 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 10,000 | 31,827 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 4,000 | 21,827 (0%) | 0% | 0 | Common Stock | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 95.28 per share. | 12 Feb 2019 | 3,270 | 23,978 (0%) | 0% | 95.3 | 311,562 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 12 Feb 2019 | 4,579 | 27,248 (0%) | 0% | 88.9 | 406,982 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 4,500 | 4,500 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 11,250 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 12 Feb 2019 | 5,356 | 10,394 (0%) | 0% | 88.9 | 476,041 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.40 per share. | 11 Feb 2019 | 2,734 | 2,734 (0%) | 0% | 23.4 | 63,976 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 5,000 | 1,546 | - | - | Stock Option (Right to Buy) | |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 11 Feb 2019 | 5,000 | 0 (0%) | 0% | 90 | 450,000 | Common Stock |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 2,734 | 6,546 | - | - | Stock Option (Right to Buy) | |
| Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.40 per share. | 11 Feb 2019 | 5,000 | 5,000 (0%) | 0% | 23.4 | 117,000 | Common Stock |
| Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 90.02 per share. | 11 Feb 2019 | 2,734 | 0 (0%) | 0% | 90.0 | 246,102 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 90.11 per share. | 11 Feb 2019 | 2,707 | 308,384 (1%) | 0% | 90.1 | 243,936 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 8,772 | 5,149 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 6,956 | 13,926 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 10,249 | 3,672 | - | - | Stock Option (Right to Buy) | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.88 per share. | 11 Feb 2019 | 6,993 | 310,673 (1%) | 0% | 88.9 | 621,538 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2019 | 11,250 | 317,666 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2019 | 4,500 | 306,416 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 90.07 per share. | 11 Feb 2019 | 6,297 | 301,916 (1%) | 0% | 90.1 | 567,173 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 91.24 per share. | 11 Feb 2019 | 171 | 308,213 (1%) | 0% | 91.2 | 15,602 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 89.50 per share. | 11 Feb 2019 | 18,971 | 311,091 (1%) | 0% | 89.5 | 1,697,878 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 88.66 per share. | 11 Feb 2019 | 5,835 | 330,062 (1%) | 0% | 88.7 | 517,321 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 11 Feb 2019 | 8,772 | 335,897 (1%) | 0% | 14.2 | 124,387 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 11 Feb 2019 | 6,956 | 327,125 (1%) | 0% | 14 | 97,384 | Common Stock |
| Yat Sun Or | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 11 Feb 2019 | 10,249 | 320,169 (1%) | 0% | 11.8 | 120,631 | Common Stock |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.58 per share. | 11 Feb 2019 | 3,728 | 3,728 (0%) | 0% | 25.6 | 95,362 | Common Stock |
| George Golumbeski | Director | Sale of securities on an exchange or to another person at price $ 90.03 per share. | 11 Feb 2019 | 2,272 | 0 (0%) | 0% | 90.0 | 204,552 | Common Stock |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.58 per share. | 11 Feb 2019 | 2,272 | 2,272 (0%) | 0% | 25.6 | 58,118 | Common Stock |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.02 per share. | 11 Feb 2019 | 7,500 | 11,228 (0%) | 0% | 29.0 | 217,650 | Common Stock |
| George Golumbeski | Director | Sale of securities on an exchange or to another person at price $ 90.07 per share. | 11 Feb 2019 | 11,228 | 0 (0%) | 0% | 90.1 | 1,011,301 | Common Stock |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 2,272 | 3,728 | - | - | Stock Option (Right to Buy) | |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 3,728 | 0 | - | - | Stock Option (Right to Buy) | |
| George Golumbeski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2019 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.70 per share. | 22 Jan 2019 | 2,000 | 17,827 (0%) | 0% | 34.7 | 69,400 | Common Stock |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2019 | 2,000 | 72,700 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2018 | 2,000 | 74,700 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.70 per share. | 06 Dec 2018 | 2,000 | 15,827 (0%) | 0% | 34.7 | 69,400 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.27 per share. | 03 Dec 2018 | 2,000 | 8,127 (0%) | 0% | 32.3 | 64,540 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2018 | 2,000 | 58,000 | - | - | Stock Option (Right to Buy) | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 68,000 | 68,000 | - | - | Stock Option (right to buy) | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Timothy D. Ocain | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 10,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Timothy D. Ocain | Senior Vice President | Sale of securities on an exchange or to another person at price $ 85.30 per share. | 01 Oct 2018 | 604 | 6,127 (0%) | 0% | 85.3 | 51,521 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Sale of securities on an exchange or to another person at price $ 84.02 per share. | 01 Oct 2018 | 14,677 | 6,731 (0%) | 0% | 84.0 | 1,233,113 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Sale of securities on an exchange or to another person at price $ 83.47 per share. | 01 Oct 2018 | 6,219 | 21,408 (0%) | 0% | 83.5 | 519,127 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Sale of securities on an exchange or to another person at price $ 82.04 per share. | 01 Oct 2018 | 3,500 | 27,627 (0%) | 0% | 82.0 | 287,142 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.27 per share. | 01 Oct 2018 | 10,000 | 31,127 (0%) | 0% | 32.3 | 322,700 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.98 per share. | 01 Oct 2018 | 15,000 | 21,127 (0%) | 0% | 20.0 | 299,700 | Common Stock |
| Timothy D. Ocain | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 1,500 | 76,700 | - | - | Stock Option (right to buy) | |
| Nathaniel S. Gardiner | Sr. VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.70 per share. | 01 Oct 2018 | 1,500 | 13,827 (0%) | 0% | 34.7 | 52,050 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 95.85 per share. | 20 Sep 2018 | 602 | 1,371 (0%) | 0% | 95.8 | 57,699 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2018 | 2,955 | 72,270 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 20 Sep 2018 | 2,955 | 4,155 (0%) | 0% | 43.5 | 128,424 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 93.02 per share. | 20 Sep 2018 | 500 | 3,655 (0%) | 0% | 93.0 | 46,509 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 93.90 per share. | 20 Sep 2018 | 453 | 3,202 (0%) | 0% | 93.9 | 42,535 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 94.75 per share. | 20 Sep 2018 | 1,229 | 1,973 (0%) | 0% | 94.8 | 116,451 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 96.89 per share. | 20 Sep 2018 | 1,371 | 0 (0%) | 0% | 96.9 | 132,842 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 93.49 per share. | 20 Aug 2018 | 659 | 310 (0%) | 0% | 93.5 | 61,613 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2018 | 2,955 | 75,225 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 20 Aug 2018 | 2,955 | 4,465 (0%) | 0% | 43.5 | 128,424 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 90.58 per share. | 20 Aug 2018 | 572 | 3,893 (0%) | 0% | 90.6 | 51,812 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 91.49 per share. | 20 Aug 2018 | 700 | 3,193 (0%) | 0% | 91.5 | 64,042 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 92.68 per share. | 20 Aug 2018 | 2,224 | 969 (0%) | 0% | 92.7 | 206,130 | Common Stock |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2018 | 8,498 | 0 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 27 Jul 2018 | 8,498 | 601,524 (3%) | 0% | 11.8 | 99,990 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 123.72 per share. | 18 Jul 2018 | 1,185 | 5,370 (0%) | 0% | 123.7 | 146,603 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 125.60 per share. | 18 Jul 2018 | 1,621 | 3,304 (0%) | 0% | 125.6 | 203,602 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 126.39 per share. | 18 Jul 2018 | 904 | 2,400 (0%) | 0% | 126.4 | 114,261 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 124.20 per share. | 18 Jul 2018 | 445 | 4,925 (0%) | 0% | 124.2 | 55,269 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 125.27 per share. | 05 Jul 2018 | 7,538 | 604,889 (3%) | 0% | 125.3 | 944,265 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 124.26 per share. | 05 Jul 2018 | 12,622 | 612,427 (3%) | 0% | 124.3 | 1,568,460 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 127.12 per share. | 05 Jul 2018 | 4,125 | 593,026 (3%) | 0% | 127.1 | 524,379 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 123.81 per share. | 05 Jul 2018 | 2,977 | 625,049 (3%) | 0% | 123.8 | 368,568 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 126.36 per share. | 05 Jul 2018 | 7,738 | 597,151 (3%) | 0% | 126.4 | 977,788 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2018 | 6,960 | 0 | - | - | Stock Option (right to buy) | |
| Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 18 Jun 2018 | 6,960 | 80,418 (0%) | 0% | 2.0 | 13,799 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.90 per share. | 18 Jun 2018 | 1,268 | 6,487 (0%) | 0% | 113.9 | 144,426 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2018 | 2,955 | 81,135 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 115.89 per share. | 18 Jun 2018 | 658 | 3,600 (0%) | 0% | 115.9 | 76,254 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 115.09 per share. | 18 Jun 2018 | 2,229 | 4,258 (0%) | 0% | 115.1 | 256,542 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 18 Jun 2018 | 2,955 | 7,755 (0%) | 0% | 43.5 | 128,424 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 121.42 per share. | 11 Jun 2018 | 5,153 | 74,069 (0%) | 0% | 121.4 | 625,658 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 119.35 per share. | 11 Jun 2018 | 2,600 | 85,558 (0%) | 0% | 119.3 | 310,305 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 117.52 per share. | 11 Jun 2018 | 300 | 88,158 (0%) | 0% | 117.5 | 35,257 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 122.17 per share. | 11 Jun 2018 | 611 | 73,458 (0%) | 0% | 122.2 | 74,648 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 120.37 per share. | 11 Jun 2018 | 6,336 | 79,222 (0%) | 0% | 120.4 | 762,655 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 105.82 per share. | 16 May 2018 | 14,032 | 638,994 (3%) | 0% | 105.8 | 1,484,913 | Common Stock |
| Jay R. Luly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 105.83 per share. | 16 May 2018 | 10,968 | 628,026 (3%) | 0% | 105.8 | 1,160,742 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2018 | 2,955 | 84,090 | - | - | Stock Option (Right to Buy) | |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 16 May 2018 | 2,955 | 8,955 (0%) | 0% | 43.5 | 128,424 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 103.84 per share. | 16 May 2018 | 400 | 8,555 (0%) | 0% | 103.8 | 41,538 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 104.80 per share. | 16 May 2018 | 800 | 7,755 (0%) | 0% | 104.8 | 83,844 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 105.57 per share. | 16 May 2018 | 2,955 | 4,800 (0%) | 0% | 105.6 | 311,951 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 16 Apr 2018 | 2,955 | 10,225 (0%) | 0% | 43.5 | 128,424 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.11 per share. | 16 Apr 2018 | 1,800 | 8,425 (0%) | 0% | 85.1 | 153,205 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.92 per share. | 16 Apr 2018 | 2,425 | 6,000 (0%) | 0% | 85.9 | 208,354 | Common Stock |
| Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2018 | 2,955 | 87,045 | - | - | Stock Option (Right to Buy) | |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 85.05 per share. | 19 Mar 2018 | 1,000 | 96,458 (0%) | 0% | 85.0 | 85,046 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 87.94 per share. | 19 Mar 2018 | 200 | 88,458 (0%) | 0% | 87.9 | 17,587 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 87.25 per share. | 19 Mar 2018 | 3,900 | 88,658 (0%) | 0% | 87.3 | 340,286 | Common Stock |
| Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 19 Mar 2018 | 3,900 | 92,558 (0%) | 0% | 86.0 | 335,412 | Common Stock |
| Bruce L.A. Carter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Lesley Russell | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Kristine Peterson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 3,750 | 3,750 | - | - | Stock Option (right to buy) | |
| Stephen Buckley | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Terry C Vance | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| George Golumbeski | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Jay R. Luly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.85 per share. | 12 Feb 2018 | 11,132 | 653,026 (3%) | 0% | 76.8 | 855,439 | Common Stock |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2018 | 20,737 | 664,158 (3%) | 0% | 0 | Common Stock | |
| Jay R. Luly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2018 | 8,600 | 643,421 (3%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2018 | 2,600 | 306,317 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2018 | 6,269 | 312,586 (1%) | 0% | 0 | Common Stock | |
| Yat Sun Or | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.85 per share. | 12 Feb 2018 | 2,666 | 309,920 (1%) | 0% | 76.8 | 204,869 | Common Stock |